TrialArchives of gynecology and obstetrics2017

A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer.

Ofer Lavie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.